Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 122, Issue -, Pages 723-730Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2016.07.009
Keywords
Drug repurposing; Tuberculosis; Rimonabant; BM212; Sila analogue; MmpL3 inhibitor
Categories
Funding
- CSIR, New Delhi [HCP001, BSC-0124]
- UGC, New Delhi
- CSIR, New Delhi
Ask authors/readers for more resources
The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation of silicon into the scaffold, resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv). The sila analogue 18a was found to be the most potent antimycobacterial compound (MIC, 31 ng/mL) from this series with an excellent selectivity index. (C) 2016 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available